Patient characteristics
| . | No. of patients* . |
|---|---|
| Median age, years (range) | 68 (44-79) |
| Male/female | 16/11 |
| κ/λ isotype | 9/18 |
| ≥2 organs involved, n (%) | 17 (63.0%) |
| Renal involvement, n (%) | 14 (51.8%) |
| Median proteinuria, mg/24 h (range) | 553 (0-14 141) |
| Cardiac involvement, n (%) | 18 (66.7%) |
| Biomarker stage II and III | 23 (85.2%) |
| Median and mean BNP, pg/mL | 174 and 252 |
| Prior treatment, median (range) | 2 (1-6) |
| Prior treatment with HDM/SCT, n (%) | 16 (59.3%) |
| Prior treatment with bortezomib, n (%) | 21 (77.8%) |
| Prior treatment with lenalidomide, n (%) | 13 (48.1%) |
| Time to enrollment, median months (range) | |
| From diagnosis | 27 (4-246) |
| From last treatment | 5 (1-89) |
| . | No. of patients* . |
|---|---|
| Median age, years (range) | 68 (44-79) |
| Male/female | 16/11 |
| κ/λ isotype | 9/18 |
| ≥2 organs involved, n (%) | 17 (63.0%) |
| Renal involvement, n (%) | 14 (51.8%) |
| Median proteinuria, mg/24 h (range) | 553 (0-14 141) |
| Cardiac involvement, n (%) | 18 (66.7%) |
| Biomarker stage II and III | 23 (85.2%) |
| Median and mean BNP, pg/mL | 174 and 252 |
| Prior treatment, median (range) | 2 (1-6) |
| Prior treatment with HDM/SCT, n (%) | 16 (59.3%) |
| Prior treatment with bortezomib, n (%) | 21 (77.8%) |
| Prior treatment with lenalidomide, n (%) | 13 (48.1%) |
| Time to enrollment, median months (range) | |
| From diagnosis | 27 (4-246) |
| From last treatment | 5 (1-89) |
HDM/SCT, high-dose melphalan and autologous stem cell transplantation.
27 patients total were enrolled in the study.